NeuroVive is extending its collaboration with Hospices Civils de Lyon (HCL) and Professor Ovize, which broadens the scope of NeuroVive's cardiovascular business area and creates the right conditions f ...

NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) today, 9 May 2014. A summary of the resolutions follows. All decisions received the required majorities.

NeuroVive, a leading mitochondrial medicine company, is presenting a breakthrough in the company's work on energy regulation at the cellular level. Based on the UK company Selcia Ltd's medical chemist ...

One of NeuroVive's largest shareholders, Maas Biolab, LLC is reducing its ownership by 359,304 shares through a share exchange with its Swedish and US shareholders. This share exchange involves Maas B ...

NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to c ...

NeuroVive Pharmaceutical AB (publ) and A1M Pharma AB (publ) have announced that the two companies are initiating a research collaboration in mitochondrial medicine. The partnership is governed by a co ...

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is reporting that the company's subsidiary NeuroVive Pharmaceutical Asia Ltd., whose registered office is in Hong Kong, ha ...

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has reported that the last of a total of 972 patients have now been enrolled and treated in its ongoing European phase III ...

Agreement expands consulting services acquired by NeuroVive, with the possibility of a broader partnership for development and commercialization services.

One of NeuroVive's largest shareholders, Baulos Capital (formerly Private Placement Sprl) and Dr. Guo Weicheng, co-founder of Sihuan Pharmaceuticals (the company's partner in China) have undertaken to ...

NeuroVive Pharmaceutical AB (publ) today announced that 22 January 2014 is the last day of trading in subscription rights in the company's ongoing new issue. The subscription period will continue unti ...